5J9 Stock Overview
Operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Fluicell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0074 |
| 52 Week High | SEK 0.13 |
| 52 Week Low | SEK 0.0001 |
| Beta | 1.77 |
| 11 Month Change | 3,600.00% |
| 3 Month Change | 155.17% |
| 1 Year Change | -94.46% |
| 33 Year Change | -99.70% |
| 5 Year Change | n/a |
| Change since IPO | -99.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5J9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3,600.0% | 1.4% | 0.8% |
| 1Y | -94.5% | -1.1% | 2.0% |
Return vs Industry: 5J9 underperformed the German Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: 5J9 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 5J9 volatility | |
|---|---|
| 5J9 Average Weekly Movement | 4,375.8% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5J9's share price has been volatile over the past 3 months.
Volatility Over Time: 5J9's weekly volatility has increased from 2448% to 4376% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Victoire Viannay | www.fluicell.com |
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet.
Fluicell AB (publ) Fundamentals Summary
| 5J9 fundamental statistics | |
|---|---|
| Market cap | €3.60m |
| Earnings (TTM) | -€2.56m |
| Revenue (TTM) | €164.12k |
21.9x
P/S Ratio-1.4x
P/E RatioIs 5J9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5J9 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.86m |
| Cost of Revenue | SEK 1.47m |
| Gross Profit | SEK 390.00k |
| Other Expenses | SEK 29.41m |
| Earnings | -SEK 29.02m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 16, 2024
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 20.93% |
| Net Profit Margin | -1,557.49% |
| Debt/Equity Ratio | 0% |
How did 5J9 perform over the long term?
See historical performance and comparison